Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Phase 1

Recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck
Metastatic Squamous Cell Carcinoma

Interventions: Biological: TBio-4101
Drug: Pembrolizumab
Drug: Platinum based chemotherapy
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin

First Posted Date: 2024-02-01

Last Posted Date: 2024-11-29

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 15

Registration Number: NCT06236425

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T

Early Phase 1

Recruiting

Conditions: T-cell Lymphoma

Interventions: Biological: hNeo-T
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-01-25

Last Posted Date: 2024-03-12

Lead Sponsor: BGI, China

Target Recruit Count: 6

Registration Number: NCT06224049

Locations: 🇨🇳
ShenZhen University General Hospital, Shenzhen, Guangdong, China

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Phase 3

Recruiting

Conditions: DLBCL - Diffuse Large B Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Dexrazoxane
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone
Drug: Lenalidomide
Drug: Pegfilgrastim

First Posted Date: 2024-01-23

Last Posted Date: 2024-08-19

Lead Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland

Target Recruit Count: 324

Registration Number: NCT06220032

Locations: 🇳🇱
NL-Breda-AMPHIA, Breda, Netherlands
🇳🇱
NL-Almelo-ZGTALMELO, Almelo, Netherlands
🇳🇱
NL-Amstelveen-AMSTELLAND, Amstelveen, Netherlands

and more 22 locations

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis

Phase 1

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: CC-97540
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-01-23

Last Posted Date: 2024-12-18

Lead Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Target Recruit Count: 98

Registration Number: NCT06220201

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇬🇧
Salford Royal Hospital, Salford, Manchester, United Kingdom
🇬🇧
Manchester Royal Infirmary, Manchester, United Kingdom

and more 34 locations

Selinexor, Cyclophosphamide and Prednisone in Myeloma

Phase 2

Completed

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Selinexor
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2024-01-19

Last Posted Date: 2024-01-19

Lead Sponsor: University of Leeds

Target Recruit Count: 66

Registration Number: NCT06212596

Locations: 🇬🇧
Guys and St Thomas NHS Foundation Trust, London, United Kingdom
🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
🇬🇧
Royal Bournemouth Hospital, Bournemouth, United Kingdom

and more 10 locations

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

First Posted Date: 2024-01-18

Last Posted Date: 2024-05-17

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT06210750

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Phase 3

Withdrawn

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Biological: Liso-cel
Drug: Idelalisib
Drug: Fludarabine
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Bendamustine

First Posted Date: 2024-01-16

Last Posted Date: 2024-04-02

Lead Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Registration Number: NCT06205290

Locations: 🇺🇸
Local Institution - 0068, Morgantown, West Virginia, United States
🇺🇸
Local Institution - 0121, New York, New York, United States
🇫🇷
Local Institution - 0036, Montpellier, Languedoc-Roussillon, France

and more 45 locations